- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01449383
Effect of Diet on Intestinal Microbiota and Obesity Markers in Adults (TORNADO)
August 13, 2012 updated by: Jana Foerster, German Institute of Human Nutrition
Molecular Targets Open for Regulation by the Gut Flora - New Avenues for Improved Diet to Optimize European Health (TORANDO): WP2 Individual Intervention Studies- Effect of Diet on Intestinal Microbiota and Obesity Markers in Adults
This study aims to investigate the direct effect of high amounts of dietary fibre and high amounts of red meat in daily diet on intestinal microbiota, anthropometry and obesity markers in healthy adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Human gut microbiota composition and its bacterial pathways are involved in many metabolic processes, including digestion of actually indigestible food components and fat storage.
Due to that it may contributes to the developement of obesity being one of the most important risk factors for many chronic diseases.
Gut microbiota is under the influence of nutrition, consumption of pro- and prebiotics can promote the growth of certain bacterial strains.
In a cross over dietary intervention this work will investigate the effect of defined diets on the intestinal microbiota in 20 healthy adults.
The diets contain either high amounts (more than 40g/d) of dietary fibre and low red meat (less than 30g/d) or low amounts (less than 20g/d) of dietary fibre and high amounts of red meat (200g/d).
Intervention periods last 3 weeks each interrupted by a 3 weeks wash out period.
Examination of participants will happen at the beginning and at the end of both interventions and will contain anthropometry, blood sample, faecal sample, urine sample and saliva sample.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 20 to 60
- obtained informed consent
- willing and able to consume defined diets
- willing and able to collect all intended samples
Exclusion Criteria:
- prevalent chronic disease, i.e. diabetes (type 1 and 2), cardiovascular diseases, cancer
- Antibiotic treatment within the last three month before start of studies
- Prevalent gastrointestinal diseases, disorders and surgeries
- Pregnancy and breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: low meat high fibre (lmhf)
consumption of less than 30g red meat per day and at least 40g dietary fibre per day
|
less than 30g red meat and at least 40g dietary fibre per day
|
Active Comparator: high meat low fibre (hmlf)
consumption of 200g red meat and not more than 20g dietary fibre per day
|
at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in gut microbiota composition
Time Frame: baseline, week 3, 6 and 9
|
baseline, week 3, 6 and 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in anthropometry
Time Frame: baseline, week 3, 6 and 9
|
Body height, body weight, circumferences of waist, hip, upper arm and leg, lower leg and the thickness of body folds at waist, back, upper arm and leg, lower leg and thorax depth and width
|
baseline, week 3, 6 and 9
|
change in blood markers
Time Frame: baseline, week 3, 6 and 9
|
clinical blood count, including Hba1c, gamma-GT, cholesterol, HDL, LDL, Triglycerides, s-creatinin, CRP
|
baseline, week 3, 6 and 9
|
change in salivary microbial composition
Time Frame: baseline, week 3, 6 and 9
|
baseline, week 3, 6 and 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jana Foerster, PhD student, German Institute of Human Nutrition Potsdam-Rehbruecke
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
October 5, 2011
First Submitted That Met QC Criteria
October 7, 2011
First Posted (Estimate)
October 10, 2011
Study Record Updates
Last Update Posted (Estimate)
August 14, 2012
Last Update Submitted That Met QC Criteria
August 13, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KBBE-2007-2-2-07_WP2.4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Markers
-
University of AarhusUnknownInflammatory Markers | Glucose Infusion | Bone MarkersDenmark
-
Mayo ClinicWithdrawnPhysical Activity | Blood Markers | Cardiac Rehab
-
Bispebjerg HospitalCompleted
-
Hadassah Medical OrganizationWithdrawnInflammatory Markers | PulpotomyIsrael
-
Hospital AvicenneRoche Diagnostics; ProBayes; Biorance Laboratoires RéunisCompletedBiological Markers | Inappropriate PrescribingFrance
-
Lund UniversityAnti-Diabetic Food CentreCompletedMood | Cognitive Performance | Cardiometabolic Risk MarkersSweden
-
Monsanto Company, LLCSolae, LLCCompletedHealthy Volunteers | Markers of Cardiovascular RiskUnited States
-
Cairo UniversityUnknown
-
University of AthensHellenic Sepsis Study GroupCompletedBiologic Markers | Clinical MarkersGreece
-
IVI MadridCompletedInflammatory Markers | Androgen Profile | IVF OutcomeSpain
Clinical Trials on low meat high fibre
-
UCSF Benioff Children's Hospital OaklandNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedInflammation | Cardiovascular Disease | Insulin Resistance | DyslipidemiaUnited States
-
University of TorontoCanadian Institutes of Health Research (CIHR)Completed
-
University of TorontoSaskatchewan Pulse Growers; Pulse CanadaCompleted
-
Pennington Biomedical Research CenterAlliance for Potato Research and EducationCompleted
-
University of LeedsCompleted
-
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training...Ondokuz Mayıs UniversityRecruitingPatient Preference | Patient SafetyTurkey
-
University of TorontoCanadian Institutes of Health Research (CIHR); Canadian Diabetes AssociationCompleted
-
University of TorontoCompletedCardiovascular Disease | Type 2 DiabetesCanada
-
Aventure ABCompleted